450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments

被引:87
作者
Cahill, N. [2 ]
Bergh, A-C [3 ]
Kanduri, M. [4 ]
Goransson-Kultima, H. [5 ]
Mansouri, L.
Isaksson, A. [4 ]
Ryan, F. [2 ]
Smedby, K. E. [6 ]
Juliusson, G. [7 ]
Sundstrom, C.
Rosen, A. [3 ]
Rosenquist, R. [1 ]
机构
[1] Uppsala Univ, Dept Immunol Genet & Pathol, Rudbeck Lab, S-75185 Uppsala, Sweden
[2] Dublin Inst Technol, Dept Biol Sci, Dublin, Ireland
[3] Dept Clin & Expt Med, Div Cell Biol, Linkoping, Sweden
[4] Sahlgrens Univ Hosp, Inst Biomed, Dept Clin Genet & Transfus Med, Gothenburg, Sweden
[5] Uppsala Univ, Dept Med Sci Canc Pharmacol & Informat, S-75185 Uppsala, Sweden
[6] Karolinska Inst, Dept Med Solna, Clin Epidemiol Unit, Stockholm, Sweden
[7] Lund Univ, Stem Cell Ctr, Dept Lab Med, Lund, Sweden
基金
瑞典研究理事会;
关键词
chronic lymphocytic leukemia; DNA methylation; 450K array; prognostic subgroups; compartments; TUMOR-NECROSIS-FACTOR; CLONAL EVOLUTION; TYROSINE KINASE; EXPRESSION; GENE; HYPERMETHYLATION; CANCER; REGULATOR; APOPTOSIS; SURVIVAL;
D O I
10.1038/leu.2012.245
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In chronic lymphocytic leukemia (CLL), the microenvironment influences gene expression patterns; however, knowledge is limited regarding the extent to which methylation changes with time and exposure to specific microenvironments. Using high-resolution 450K arrays, we provide the most comprehensive DNA methylation study of CLL to date, analyzing paired diagnostic/follow-up samples from IGHV-mutated/untreated and IGHV-unmutated/treated patients (n = 36) and patient-matched peripheral blood and lymph node samples (n = 20). On an unprecedented scale, we revealed 2239 differentially methylated CpG sites between IGHV-mutated and unmutated patients, with the majority of sites positioned outside annotated CpG islands. Intriguingly, CLL prognostic genes (for example, CLLU1, LPL, ZAP70 and NOTCH1), epigenetic regulator (for example, HDAC9, HDAC4 and DNMT3B), B-cell signaling (for example, IBTK) and numerous TGF-beta and NF-kappa B/TNF pathway genes were alternatively methylated between subgroups. Contrary, DNA methylation over time was deemed rather stable with few recurrent changes noted within subgroups. Although a larger number of non-recurrent changes were identified among IGHV-unmutated relative to mutated cases over time, these equated to a low global change. Similarly, few changes were identified between compartment cases. Altogether, we reveal CLL subgroups to display unique methylation profiles and unveil methylation as relatively stable over time and similar within different CLL compartments, implying aberrant methylation as an early leukemogenic event. Leukemia (2013) 27, 150-158; doi:10.1038/leu.2012.245
引用
收藏
页码:150 / 158
页数:9
相关论文
共 50 条
  • [1] SUPPRESSIN - AN ENDOGENOUS NEGATIVE REGULATOR OF IMMUNE CELL ACTIVATION
    BAN, EMH
    LEBOEUF, RD
    [J]. IMMUNOLOGIC RESEARCH, 1994, 13 (01) : 1 - 9
  • [2] Controlling the false discovery rate in behavior genetics research
    Benjamini, Y
    Drai, D
    Elmer, G
    Kafkafi, N
    Golani, I
    [J]. BEHAVIOURAL BRAIN RESEARCH, 2001, 125 (1-2) : 279 - 284
  • [3] CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia
    Buhl, AM
    Jurlander, J
    Geisler, CH
    Pedersen, LB
    Andersen, MK
    Josefsson, P
    Petersen, JH
    Leffers, H
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 76 (06) : 455 - 464
  • [4] The microenvironment in mature B-cell malignancies: a target for new treatment strategies
    Burger, Jan A.
    Ghia, Paolo
    Rosenwald, Andreas
    Caligaris-Cappio, Federico
    [J]. BLOOD, 2009, 114 (16) : 3367 - 3375
  • [5] ZAP-70 intron1 DNA methylation status: Determination by pyrosequencing in B chronic lymphocytic leukemia
    Chantepie, Sylvain P.
    Vaur, Dominique
    Grunau, Christoph
    Salauen, Veronique
    Briand, Melanie
    Parienti, Jean-Jacques
    Heutte, Natacha
    Cheze, Stephane
    Roussel, Mikel
    Gauduchon, Pascal
    Leporrier, Michel
    Krieger, Sophie
    [J]. LEUKEMIA RESEARCH, 2010, 34 (06) : 800 - 808
  • [6] Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas
    Chaperot, L
    Plumas, J
    Jacob, MC
    Bost, F
    Molens, JP
    Sotto, JJ
    Bensa, JC
    [J]. EXPERIMENTAL HEMATOLOGY, 1999, 27 (03) : 479 - 488
  • [7] Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL
    Chen, Shih-Shih
    Claus, Rainer
    Lucas, David M.
    Yu, Lianbo
    Qian, Jiang
    Ruppert, Amy S.
    West, Derek A.
    Williams, Katie E.
    Johnson, Amy J.
    Sablitzky, Fred
    Plass, Christoph
    Byrd, John C.
    [J]. BLOOD, 2011, 117 (03) : 862 - 871
  • [8] Corcoran M, 2005, HAEMATOLOGICA, V90, P1078
  • [9] CORDINGLEY FT, 1988, LANCET, V1, P969
  • [10] Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation
    Fabbri, Giulia
    Rasi, Silvia
    Rossi, Davide
    Trifonov, Vladimir
    Khiabanian, Hossein
    Ma, Jing
    Grunn, Adina
    Fangazio, Marco
    Capello, Daniela
    Monti, Sara
    Cresta, Stefania
    Gargiulo, Ernesto
    Forconi, Francesco
    Guarini, Anna
    Arcaini, Luca
    Paulli, Marco
    Laurenti, Luca
    Larocca, Luigi M.
    Marasca, Roberto
    Gattei, Valter
    Oscier, David
    Bertoni, Francesco
    Mullighan, Charles G.
    Foa, Robin
    Pasqualucci, Laura
    Rabadan, Raul
    Dalla-Favera, Riccardo
    Gaidano, Gianluca
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2011, 208 (07) : 1389 - 1401